Traumatic brain injury is an important cause of global morbidity and mortality. After an initial injury, there is a cascade of cellular and molecular events that ultimately lead to cell death. Therapies aim to both counteract these mechanisms and replenish the lost cell population in order to improve recovery. The adult mammal brain has at least two neurogenic regions that maintain physiological functions: the subgranular zone of the dentate gyrus in the hippocampus, which produces neurons that integrate locally, and the subventricular zone (SVZ) adjacent to the lateral ventricles, which produces neuroblasts that migrate through the rostral migratory stream (RMS) to the olfactory bulbs. Brain injuries, as well as neurodegenerative diseases, induce the SVZ to respond by increasing cell proliferation and migration to the injured areas. Here we report that cells migrate from the SVZ and RMS to the injured cortex after traumatic brain injury in mice, and that the physiological RMS migration is not impaired. We also show that Prokineticin 2 (PROK2), a chemokine important for the olfactory bulb neurogenesis, expressed exclusively by cortical microglia in the cortex as early as 24 h after injury. We then show that administration of a PROK2 receptor antagonist decreases the number of SVZ cells that reach the injured cortex, while injection of recombinant PROK2 into the cortex of uninjured mice attracts SVZ cells. We also demonstrate that cells expressing PROK2 in vitro directionally attract SVZ cells. These data suggest that PROK2 could be utilized in regeneration efforts for the acutely injured mammalian cortex.
Introduction
Traumatic brain injury (TBI) is an important cause of global morbidity and mortality. In the United States alone, there were approximately 2.5 million people hospitalized for TBI in 2010 with a mortality of 2% (Centers for Disease Control and Prevention, 2015) . The people who survive can experience significant morbidity from cognitive, behavioral, motor and somatic symptoms. Currently there are an estimated 3.2 million-5.3 million people living with TBI-related disabilities in the US. The pathophysiology of TBI includes primary and secondary injuries. The primary injury results directly from the physical trauma. The secondary injury develops from a cascade of cellular and molecular degenerative mechanisms. It is the latter that causes most of the brain injury and it is therefore a target of therapies (Galgano et al., 2016) .
One important therapy involves utilizing endogenous neural stem cells to proliferate and migrate to injured areas (Altman, 1963; Chang et al., 2016; Dizon et al., 2010; Reynolds and Weiss, 1992; Eriksson et al., 1998; Reis et al., 2017; Harting et al., 2009; Park et al., 2012; Sun et al., 2011) . The main neurogenic areas in the adult brain are the subgranular zone (SGZ) of the hippocampus dentate gyrus, and the subventricular zone (SVZ) adjacent to the lateral ventricles. The neural stem cells in the SVZ give rise to neuroblasts that normally migrate through the rostral migratory stream (RMS) to the olfactory bulbs where they differentiate into olfactory neurons (Lois and AlvarezBuylla, 1994; Gage, 2000; Alvarez-Buylla and Garcia-Verdugo, 2002) .
Prokineticin 2 (PROK2) is a chemokine involved in olfactory bulb neurogenesis and directing neuroblast migration (Ng et al., 2005) . PROK2 activates two G-protein coupled receptors, PKR1 and PKR2, which are differentially expressed throughout the brain. They confer a broad spectrum of functions including regulation of circadian rhythm, temperature and energy expenditure (Cheng et al., 2002; Zhou et al., 2012) . Recently it has been reported that PROK2 is upregulated in some https://doi.org/10.1016/j.mcn.2018.10.004 Received 6 August 2018; Received in revised form 13 October 2018; Accepted 30 October 2018 brain pathologies such as Parkinson's and Alzheimer's disease and stroke (Gordon et al., 2016; Severini et al., 2015; Cheng et al., 2012) .
Here we investigated the role of PROK2 in a traumatic brain injury model. We show, for the first time, that PROK2 is expressed by microglia at the injured site within one day of the injury and that it enhances migration of SVZ neuroblasts to the injured area.
Understanding the function of PROK2 in brain injuries is of great importance for the comprehension of the pathological process, and as a consequence for the development of repair strategies.
Material and methods

Animals
Male C57BL/6 mice aged 2 days, 6 weeks or 12 weeks were maintained under a 12-h light/dark cycle with access to water and food ad libitum. For in vivo experiments, four to five animals were used for each experimental group. For in vitro experiments, the SVZ was dissected from 4 animals. All experimental procedures and animal handling were performed in accordance with the UK Animals (Scientific Procedures) Act of 1986 Home Office regulations and approved by the Committee for Ethics in the Use of Animals from Universidade Federal de São Paulo (CEUA 747918).
Surgical procedures
The animals were anesthetized with xylazine (Ceva) 10 mg/kg of body weight, ketamine (Syntec) 100 mg/kg and acepromazine (Vetnil) 1 mg/kg then placed in a stereotaxic apparatus. A blunt metal needle was attached to the stereotaxic device and gently inserted three times into the motor cortex [AP 0 mm, ML +1 mm, DV −0.75 mm (Paxinos and Franklin, 2001) ]. After producing the lesion, the skin was stapled and the animals were returned to their cages for recovery. The animals received analgesia (acetaminophen 1 mg/mL, EMS) in their drinking water for two days after the surgery.
BrdU and EdU administration
For proliferation studies, two protocols of BrdU intraperitoneal injections were used: one injection of BrdU (Sigma, 50 mg/kg of body weight, in 0.9% NaCl solution) 30 min after the injury and two more injections every 2 h; and one injection 6 h after the injury and four more injections every 24 h. For migration studies, the animals were injected with four doses of BrdU every 12 h with a washout period of 15 h before the injury or recombinant PROK2 administration, and EdU (Invitrogen) in a single dose (50 mg/kg of body weight) 4 h after the injury. The protocols used are indicated in the results section.
PKRA7 and PROK2 administration
The PROK2 receptor antagonist PKRA7 (20 mg/kg, Merck) was administered via intraperitoneal injection 1 h after the injury and then every 24 h for 3 days. Control animals were injected with 10% DMSO. Recombinant PROK2 (10 pMol, Peprotech, USA) was administered in the motor cortex as a single dose [AP 0 mm, ML +1 mm, DV −0.75 mm (Paxinos and Franklin, 2001) ]. Control animals were injected with 0.9% NaCl solution.
Immunohistochemistry and image acquisition
On the last day of the experiment (indicated in the results section), mice were anesthetized and intracardially perfused with ice-cold paraformaldehyde (4% PFA) in 0.1 M PBS. The brains were removed, postfixed in 4% PFA overnight at 4°C, and cryopreserved in 30% sucrose solution at 4°C for 48 h. The brains were frozen on dry ice. Using a Leica CM1850 cryostat, 30 μm serial tissue sections were cut with 120 μm intervals for RMS sections and 360 μm intervals for SVZ sections. Free-floating sections were washed in 0.01 M phosphate buffer saline and treated with 50 mM Glycine for 15 min. Blocking was performed with 5% normal goat serum and 0.1% Triton X-100 for 1 h. Primary antibodies were diluted in blocking solution and incubated on sections overnight at 4°C. Secondary antibodies were diluted in blocking solution and DAPI (Sigma, 1:1000), and incubated on sections for 1 h at room temperature. Sections were washed with phosphate buffer and mounted using fluoromount (Electron Microscopy Sciences). For BrdU staining, the sections were treated with 2 N HCl for 30 min at 37°C after the initial wash and were not colored with DAPI. EdU was detected using the Click-iT™ EdU Alexa Fluor™ 488 Imaging Kit (Molecular Probes) according to manufacturer instructions. The following primary antibodies were used: rat anti-BrdU (1:500, Bio-Rad OBT0030), guinea pig anti-Dcx (1:500, Millipore, ab2253), chicken anti-GFAP (1:500, Millipore ab5541), rabbit anti-PROK2 (1:200, Abcam ab76747), mouse anti-CD45 (1:100, Affymetrix 48-0451-80), goat antiIba1 (1:400, Abcam ab5076). Alexa Fluor™ secondary antibodies (1:500, Molecular Probes) were used. A Zeiss 710 confocal microscope was used for image acquisition. Images were acquired from 3 sections per animal, and 15 μm with 1.5 μm intervals per section were imaged and used for analysis and cell counting. Fiji was used for image analysis; cells were counted using the Cell Counter Plugin (Schindelin et al., 2012) .
qPCR
A sample of the injured cortex and both olfactory bulbs were used for RNA extraction with Trizol® (Invitrogen) and quantified using the spectrophotometer NanoVue Plus (GE Healthcare). One μg of total RNA was reverse-transcribed using Oligo(dT)15 Primer (Promega) and the ImProm-II Reverse Transcription System (Promega) with Recombinant RNasin® Ribonuclease inhibitor (Promega) and MgCl 2 . Quantitative PCR (qPCR) was performed using 20 ng cDNA and Brilliant® II SYBR® Green QPCR Master Mix (Stratagene), in an Applied Biosystems® 7500 Real-Time PCR System. Thermal cycling included 95°C for 10 min, 40 × 95°C for 15 s, 60°C for 1 min and 72°C for 30 s. The dissociation curve was performed at 95°C for 1 min, 60°C for 30 s and 95°C for 30 s. The primers used were: Prok2 -sense 5′-CGGAGGATGCACCACACCT-3′ and antisense 5′-TTTCCGGGCCAAGCAAATAAACCG-3′, Cxcl12 -sense 5′-ATCCTCAACACTCCAAACTGTGCC-3′, and antisense 5′-TTCAGACCT AGGCTCCTCCTGTAA-3′, Hprt -sense 5′-CTCATGGACTGATTATGGAC AGGAC-3′ and antisense 5′-GCAGGTCAGCAAAGAACTTATAGCC-3′.
Plasmids
Murine Prok2 coding sequence was amplified from the cDNA of cortical samples from five injured mice by PCR using Pfu Recombinant DNA polymerase, (Thermo Fisher Scientific, cat#EP0501) according to manufacturer instructions. The primers for Prok2 were: forward 5′-GGAATTCCATGGGGGACCCGCGCT-3′ and reverse 5′-CGGGATCCC CATTTCCGGGCCAAGCAAA-3′; the restriction sites EcoRI and BamHI, respectively, are underlined. The PCR product was digested with the indicated restriction enzymes and cloned into the pEGFP-N3 (Clontech) mammalian expression vector. For the control empty vector, EcoRI/ BamHI digested plasmid was treated with blunting enzyme from the CloneJET PCR cloning kit (Thermo Fischer Scientific, cat#K1239) and re-ligated with T4 DNA ligase (NEB, cat#M0202V). The plasmids were expanded in DH5α E. coli and purified with a maxi-prep kit according to the supplier's protocol (Qiagen, Valencia, CA, USA). The constructs were verified by restriction analysis and DNA sequencing with the BigDye Terminator v3.1 Cycle Sequencing kit (Applied, cat#4334755).
(Gibco), 10% fetal bovine serum (Cultilab), 1% glutamine (Sigma) and 1% Penicillin/Streptomycin (Gibco) at 37°C and 5% CO 2 . Once 70% confluency was achieved, cells were transfected with pEGFP-PK2 or pEGFP plasmids using the Calcium Phosphate method. Briefly, 15 μg DNA, 2 M CaCl 2 and H 2 O were mixed in a vial and 2× HBS was added after. The mix was gently added in different locations on the plate, and the cells were incubated for 24 h at 37°C and 5% CO 2 . The medium was changed after that and cells were incubated for another 24 h. The cells were then trypsinized and cultured as hanging drops at a density of 2.5 × 10 6 /mL. HEK293T spheroids were allowed to form for 1 day.
Neural stem cell culture
Neural stem cells were obtained from 6 weeks old C57BL/6 mice. Briefly, mice were euthanized and their brains were removed. The SVZ was then dissected and the cells were dissociated by incubation with Accutase (Gibco) for 5 min at 37°C. After mechanical dissociation, the cells were strained in a 40 μm mesh (BD Biosciences) and plated in Poly-HEMA (Sigma) precoated flasks, in complete medium containing DMEM/F12 1:1 (Gibco), 2% B27 supplement (Gibco), 20 ng/mL EGF (Sigma), 20 ng/mL FGF2 (R&D Systems), 1% penicillin/streptomycin (Gibco) and 5 μg/mL heparin (Sigma). After neurosphere formation (100-150 μm), they were passaged and allowed to form once again. Neurospheres were used for experiments after the third passage.
Co-culture
Transfected HEK293T spheroids and neurospheres were plated very closely in a 20 μL drop of 6 mg/mL matrigel (BD). One spheroid and one neurosphere were plated in each well. The wells were filled with complete medium without growth factors and incubated at 37°C and 5% CO 2 for 5 days. The experiment was performed twice with at least 3 biological replicates per experiment.
Astrocyte culture
Cells were extracted from 2 day old C57BL/6 mice. After euthanasia, the cortices were dissected, chopped and washed in a Ca 2+ e Mg 2+ free Hanks solution containing 10% bovine serum and 1% penicillin/streptomycin in a Versene solution. The tissue was incubated with 0.25% trypsin (Gibco) and 1 mM EDTA for 30 min at 37°C before mechanical dissociation. The cells were washed then resuspended and cultured as a monolayer in medium containing DMEM/F12 1:1, 10% inactivated bovine serum and 1% penicillin/streptomycin. The medium was changed 24 h later then every 48 h. For qPCR experiments, astrocytic RNA was extracted using the PureLink RNA Micro Kit (Invitrogen) according to the manufacturer protocol. cDNA synthesis and qPCR were completed as described for qPCR. For quantitative experiments, proteins were extracted using RIPA buffer and ELISA was performed using the Duoset dy460 ELISA Kit (Red Systems) following manufacturer's protocol.
Statistics
Statistical analysis was performed using GraphPad Prism. The graphs presented show the mean ± standard error. The difference between groups was assessed using Student's t-test unless stated otherwise. Differences were considered statistically significant when p ≤ 0.05.
Results and discussion
Cortical injury induces astrogliosis and cell proliferation in the cortex and SVZ
To simulate open head injury, we used a model of brain injury caused by a puncture wound (Fig. 1c) . This injury was restricted to the cortex and did not involve white matter (Fig. 1g) . The injury caused astrogliosis in the SVZ, corpus callosum and cortex to appear as early as 12 h after the injury (Fig. 1e) . In order to label cells proliferating in response to the injury, we administered BrdU after 30 min and two further doses every 2 h (Fig. 1a) . We observed cell proliferation in the SVZ in the 18 h post injury (Fig. 1d-f) but not in the cortex adjacent to the injury (data not shown). In a separate experiment, we administered BrdU after 6 h and then every 24 h for 4 days (Fig. 1b) . We found many BrdU+ cells in the cortex, which were concentrated near the injury site (Fig. 1g) . The cortical BrdU+ cells included proliferating GFAP+ astrocytes (Fig. 1h) .
SVZ-derived neuroblasts migrate to the cortex after cortical injury
We next wanted to evaluate the migration of SVZ cells towards the injured cortex, so we administered BrdU to the animals every 12 h for two days prior to the injury (Fig. 2a ). An undamaged brain contains two regions with constant cell proliferation, the neurogenic SVZ and SGZ, so any BrdU+ cells found in the brain would be derived from these regions. To label the cells that proliferated in response to the injury, we also administered EdU to the animals 4 h after performing the injury (Fig. 2a) . The administration of the thymidine analog BrdU up to 4.5 h after the injury does not label cortical cells (Fig. 1) , so any EdU+ cell would be derived from the neurogenic regions. The SGZ produces cells that integrate into the hippocampus and there is no demonstration in the literature that these cells migrate to the injured cortex. That said, we found many SVZ derived BrdU+ and EdU+ cells leaving the SVZ, in the corpus callosum and cortex leading to the site of injury, further emphasizing their origin in the SVZ, and mainly near the site of injury (Fig. 2c) , indicating that not only the cells that proliferate in response to the injury, but also the ones that are physiologically proliferating in the SVZ migrate to injured areas. Some of the cells we found were BrdU +EdU+, indicating that a portion of the SVZ cells underwent cell cycle re-entry after the injury and migrated to the cortex. BrdU+ cells also appeared to migrate from the rostral migratory stream en route to the olfactory bulb, with many seen deviating their original course and migrate towards the injured cortex (Fig. 2d ) Many neuroblasts were also found near the site of the injury (Fig. 2e,f) . In the inner cortical layers, in proximity to the corpus callosum, the neuroblasts presented a migratory morphology differently from the RMS (Fig. 2e) . The neuroblasts did, however, appear to be migrating along a route, which is consistent with descriptions of neuroblasts migrating using blood vessels and reactive astrocytes as a scaffold (Saha et al., 2013) . At the site of the injury, the neuroblasts had a smaller cell body and increased complexity of dendrites (Fig. 2f , red Dcx+ cells). We speculate that this appearance reflects an attempt to integrate into the injured area and make new synaptic connections during the early post injury period.
Cell migration from the SVZ to the injured cortex is not common to all types of injury, and it depends on the damage context and extent; large lesions can trigger intense cell migration, especially when the damage reaches the white matter, and smaller injuries can mobilize fewer, if any, SVZ cells (Ohab et al., 2006; Shimada et al., 2010; Jin et al., 2003) . Here we show that in the TBI model of brain injury we used, SVZ cells migrate towards the cortex despite the small extent of the injury, suggesting that not only the extent, but also the type of the injury influences the mobilization of cells from the SVZ neurogenic niche. 
Cortical injury does not impair migration of SVZ cells to the olfactory bulb
Our protocol for BrdU and EdU incorporation allows us to differentiate between cells generated before and after the injury. BrdU+ cells are the ones originated by the continuous proliferation of SVZ neural stem cells before the injury and EdU+ cells are generated in response to the injury (Fig. 3a) . We found that fewer BrdU+ cells remained in the SVZ 7 days after the injury (Fig. 3d,e) , but there was no difference in the number of EdU+ cells between the groups (Fig. 3f) . We also found no difference in the number of BrdU+EdU+ cells (Fig. 3g) indicating no changes in the cell cycle re-entry index. The percentage of BrdU+ cells that were Dcx + was not altered by the injury (Fig. 3h) , but more EdU + cells were also Dcx + after the injury (Fig. 3i) . These data indicate that more SVZ cells generated after the injury produced neuroblasts (Dcx + EdU+ cells) that emigrated from the SVZ. Goings et al. (2002) found that the number of physiologically proliferating cells in the SVZ decreased as early as 6 h after injury, accompanied by a decrease of PSA-NCAM+ neuroblasts. Brain injuries increase cell proliferation in the SVZ (Saha et al., 2013; Theus et al., 2010; Radomski et al., 2013) , but since we did not see more EdU+ cells in the SVZ, and the fact that more Dcx+ EdU+ cells were found in the SVZ 7 days after the injury we hypothesized that an increased number of cells that proliferated after the injury differentiated into neuroblasts. One explanation would be that the decrease seen by Goings et al. (2002) is reverted by a later increase in the production of neuroblasts in the SVZ.
What happens to the physiological migration of SVZ-derived neural stem cells after brain injuries is still controversial in the literature. The double labeling protocol using thymidine analogs incorporation to follow SVZ-derived cells is broadly used to trace the cells and find their final destination after injury. However, the results largely depend on the incorporation protocol that was used, and since most of the experiments are of end point type, the results also depend on how many days after the injury the brain was analyzed. Here we show that the number of BrdU+ and EdU+ cells in the RMS was not altered 7 days after the injury (Fig. 3k-m) . We found some BrdU+ and EdU+ cells out of the RMS in the injured group, and we also showed that some cells migrate out of the RMS after the injury (Fig. 2d) , but we hypothesize that the lack of alteration in the RMS migration is due to increased proliferation in the SVZ, thus compensating for the normal migration of neuroblasts towards the olfactory bulb.
Many soluble molecules produced and secreted at a cortical acute injury site have been reported, especially chemokines derived from immune cells and astrocytes CXCL12 is one of the chemokines which expression is increased after acute injury to the brain and that attracts neuroblasts to an injury site (Galindo et al., 2011; Dalgard et al., 2012) . We were interested in knowing if the migrating neuroblasts responded differently to two distinct chemotactic stimuli, CXCL12, as found at the injury site, and PROK2, constitutively expressed in the olfactory bulb and considered one of the key chemoattractants to direct neuroblasts that arrive to the olfactory bulb (Ng et al., 2005) .
Prokineticin 2 is expressed in the injured cortex
PROK2 is mostly expressed in the granular and periglomerular layers of the olfactory bulb where it plays a role in neurogenesis . We hypothesized that PROK2 may also have a role in migration following traumatic brain injury. Since to our knowledge there was no information regarding the expression of PROK2 following brain injury, we investigated Prok2 mRNA expression in the olfactory bulb in different time points after the TBI model (Fig. 4a) . We found that Prok2 expression decreased one day after the injury, but after the second day, expression was more than twofold. After four days the expression returned to basal level and remained for at least 14 days. The sudden decrease in Prok2 expression could be a general response to injuries, since a similar injury was performed in the cerebellum also caused decrease in Prok2 mRNA expression (data not shown). The following rapid overexpression could be a rebound, probably to prevent further consequences to the RMS migration that could have happened by the diminished Prok2 in the olfactory bulb.
Interestingly, we found that Prok2 expression was upregulated in the injured cortex, beginning one day after the injury, with the highest levels achieved on the second day, and returning to normal level after 7 days (Fig. 4b) . The analysis of the cortex tissue at the injury site showed that PROK2 was also upregulated at the protein level, and the PROK2-rich area was concentrated in the region surrounding the site of needle entry, inside the cells and in the extracellular space (Fig. 4c) .
We next investigated which cells express PROK2 after brain injury. Previous literature has shown that PROK2 is mostly expressed in neurons in cortical cell cultures. There was discrete expression in astrocytes and no expression in microglia. When the cells were challenged with glutamate-and amyloid-beta-induced toxicity, however, PROK2 was upregulated in both neurons and astrocytes Severini et al., 2015) . We were surprised to find that PROK2 was not expressed in vivo by astrocytes (GFAP+ cells) or immature neurons (Dcx + cells) in vivo 7 days after the injury (Fig. 4d) . Brain injuries cause a disruption of the blood-brain barrier turning the blood vessels permeable to blood-derived factors and cells (Gyoneva and Ransohoff, 2015) . PROK2 is expressed by neutrophils and monocytes (LeCouter et al., 2004) , and increases in PROK2 in neuropathologies have been associated to infiltrated cells (Giannini et al., 2009; Abou-Hamdan et al., 2015) . With that in mind we investigated if hematopoietic cells that had infiltrated the brain parenchyma were the PROK2+ cells. We conducted an immunohistochemistry with PROK2 and CD45 antibodies. CD45, also known as leukocyte common antigen, is expressed in all nucleated hematopoietic cells and resting microglia, and was then used as a marker of these cells. No colocalization was found with the two antibodies (Fig. 4d) . We next conducted an immunohistochemistry with PROK2 and Iba1 (reactive microglia marker) antibodies. All of the PROK2+ cells were also Iba1+, demonstrating that reactive microglia is the source of PROK2. We did not identify other PROK2 expressing cells. Despite the previous report of no expression of PROK2 by cultured microglia , we show that its expression is only induced after brain injury, and it is not detected in the intact brain.
PROK2 modulates the migration of SVZ cells to the injured cortex
The expression of PROK2 in injured cortex, as well as its chemotactic role in the olfactory bulbs, raised the possibility of it also having a chemotactic role in injury cortex. We therefore performed BrdU migration experiments in mice that were treated with PKRA7, a PROK2 antagonist, or a DMSO control (Fig. 5a ). These mice were administered we used a commercially available PROK2 antagonist, PKRA7, in mice submitted to brain injury. We administered BrdU for 2 days prior to the injury to label SVZ cells. They were injected with PKRA7 or DMSO 1 h after injury then daily for 3 days, before being sacrificed on day 4. We found fewer BrdU+ cells in the cortex of PKRA7 treated mice compared to controls, which was consistent with our initial hypothesis (Fig. 5b,c) . We performed a similar experiment by injecting recombinant PROK2 or normal saline into the cortices of uninjured mice (Fig. 6b) . We found more than twice as many BrdU+ cells in the cortices of the PROK2 injected group mice (Fig. 6c, d, f) . These data suggest that PROK2 plays . PK2 does not induce the expression of pk2 or cxcl12 in astrocytes and microglia in vitro. cxcl12 and pk2 expression by astrocytes and microglia in culture treated with recombinant PK2 for 2 days. Expression was normalized to hprt. Graphs show mean ± SEM.
M.V. Mundim et al. Molecular and Cellular Neuroscience 94 (2019) 1-10 a crucial role in recruiting SVZ cells to injured areas. We further confirmed the chemotactic role of PROK2 using in vitro migration assays. We co-cultured SVZ-derived neurospheres and spheroids of either PROK2-expressing or control 293 T cells. The neurospheres and spheroids were placed within a collagen matrix so that secreted factors from the spheroids could attract cells emigrating from the neurospheres. When the neurospheres were co-cultured with control 293 T cells, the emigration of cells from the neurospheres was symmetric. When the neurospheres were co-cultured with the PROK2-expressing 293 T cells, however, the emigration of cells from the neurospheres was asymmetric with more cells migrating towards the spheroid. The cells also migrated a greater distance from the neurospheres in that direction (Fig. 6a) . Similar results were found using cells expressing a human form of PROK2 and SVZ explants (Ng et al., 2005) .
Besides the physiological role of PROK2 as modulator of olfactory bulb neurogenesis (Ng et al., 2005) , generation of circadian rhythms (Cheng et al., 2002; Li et al., 2006) , angiogenesis (LeCouter et al., 2001; LeCouter et al., 2003) , reproduction (Maldonado-Perez et al., 2007) and gastrointestinal motility (Li et al., 2001 ), PROK2 has recently been implicated in brain injuries and neurodegenerative diseases. In a mouse model of Parkinson disease PROK2 expression was induced in dopaminergic neurons and substantia nigra, promoting neuroprotection by activating ERK and Akt signaling pathways (Gordon et al., 2016) . PROK2 was also showed to be an endangering mediator for cerebral damage in an ischemic model , to modulate neuropathic pain in a chronic constriction injury model , and to mediate amyloid-beta neurotoxicity in an Alzheimer's disease model (Severini et al., 2015) . To our knowledge this is the first report of cortical PROK2 induction after a traumatic brain injury.
The infiltration of neutrophils, lymphocytes and monocytes in the brain parenchyma after the initial injury triggers a wave of proinflammatory cytokines leading to the recruitment of immune cells and microglia (Lozano et al., 2015) . Microglial activation induces the production and release of more proinflammatory cytokines and thereby increase the production of chemokines (Chodobski et al., 2011) . PROK2 also upregulates a variety of chemokines (Curtis et al., 2013) , and since chemokines are able to attract SVZ cells to injured areas (Filippo et al., 2013) , PROK2 could indirectly promote chemoattraction of these cells by upregulating other chemokines, such as CXCL12. To test this hypothesis, we treated an astrocyte/microglia culture with recombinant PROK2 for 2 days and analyzed the expression of Cxcl12 mRNA by qPCR. CXCL12 is a chemokine known to recruit SVZ cells to injured areas (Filippo et al., 2013) . Cxcl12 mRNA was not increased in the treated cells, but decreased instead (Fig. 7) . Prok2 mRNA was also not altered, indicating there was not a positive feedback loop of activation. In vitro, CXCL12 is only detected in astrocytes when they are activated (Dra. Marcella Reis personal communication). Indeed, we were not able to detect CXCL12 in the supernatant of astrocytes/microglia culture, even when they were treated with PROK2, measured by ELISA (data not shown). These data show that PROK2 was not able to induce the expression and secretion of CXCL12. We cannot rule out that PROK2 induces the production of other chemokines that then recruit SVZ cells, but since we demonstrated that in vitro PROK2 can directly attract SVZ cells, it is possible that PROK2 act by a somatory of direct and indirect mechanisms.
Brain injuries trigger a cascade of pathophysiological processes that ultimately lead to cell death. The migration of SVZ cells to the injured area could help to replenish the cell population. Understanding the role of PROK2 in the TBI context can help to formulate strategies of intervention after brain injuries, aiming not only its targets in the downstream molecular pathways, but potentially PROK2 itself. PROK2 is a druggable molecule and could be used as a modulator of SVZ cell migration, augmenting the amount of cells recruited to lesion areas, thus helping to promote a better recovery of acutely injured brain.
Conclusion
We showed here that PROK2 is upregulated and expressed by microglia after cortical TBI in mice, and that PROK2 is able to recruit SVZderived cells to the site of injury. This is a new role described for PROK2 in the pathological context and it represents a potential target for stem cell-based therapies.
